Kering SA reported third-quarter revenue roughly in line with expectations, but its share price fell due to weak retail performance, especially in China. While non-Gucci brands like Saint Laurent and Bottega Veneta grew retail sales by 2%, Gucci's sales declined 9% year-over-year, driven by significant price cuts in China reflecting ongoing demand challenges and inventory reductions. The company’s future outlook depends on stabilization in China, stronger local product appeal, and margin improvements before a more positive rating can be considered.
Kering SA's recent performance is provided here as context for readers. For those tracking the Consumer Cyclical sector, 75 of 134 US stocks rose while 33 fell on Pluang. Notable prices include TSLA at USD 379.01 with a 1-day change of +1.84%, NEGG at USD 9.55 down 1.55%, and AZO at USD 3,153.00 down 1.49%, as of Oct 26, 2026 18:31 WIB.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
